Loading...
Jupiter Wellness, Inc.
JUPWW•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.32
$-0.08(-20.00%)

The company's financials show resilient growth, with revenue advancing from $132702.00 in Q4 2023 to $110213.00 in Q3 2024. Gross profit remained healthy with margins at -265% in Q3 2024 compared to -112% in Q4 2023. Operating income hit $0.00 last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$11.45M. Net income dropped to -$11.93M, while earnings per share reached -$0.21. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan